Viana et al. [I] described their experience with etoposide (VP-16) as initial therapy in the management of patients with Langerhans cell histiocytosis (LCH). However, caution should be used in advocating the use of an epipodophyllotoxin as the "drug of choice" for the treatment of this disorder. Alt
Etoposide in the treatment of six children with langerhans cell histiocytosis (histiocytosis X)
β Scribed by Viana, Marcos Borato ;Oliveira, Benigna Maria ;Silva, Celia Maria ;Leite, Virginia Hora Rios
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 548 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
Six children received etoposide as the single agent for treatment of Langerhans cell histiocytosis (LCH; histiocytosis X). Five were less than 2 years old at diagnosis. All had multiorgan involvement; one had liver and pulmonary dysfunction. Two infants also had clinical signs of immune deficiency. Complete response was observed in five. There was no major toxicity. Although three of four evaluable patients relapsed, the drug was considered useful in moving the children from a symptomatic to an asymptomatic clinical status. Etoposide may become a "first-line" drug in the treatment of systemic LCH, especially when the side effects of steroid therapy are considered unacceptable.
π SIMILAR VOLUMES
Background. Manifestations of Langerhans cell histiocytosis (LCH) in children range from only a rash, to bony lesions accompanied by pain, to major organ disease. When the central nervous system (CNS) is affected, the LCH patient may exhibit signs and symptoms of hypothalamic and pituitary dysfuncti
Sixty-four patients with biopsy-proven Langerhans' cell histiocytosis (LCH, formerly designated as histiocytosis X) were managed at the Children's Hospital of Philadelphia from 1970 through 1984. Their median age was 3 yr (range, 0.1-22 yr). Thirty-three patients had localized lesions affecting a bo
To the Editor: We here describe a 3-year-old-boy who was treated for LCH using vinblastine, etoposide and prednisone according to the International Langerhans Cell Histiocytosis Study I. The patient was admitted in March 1993 with multiple bone lesions, diabetes insipidus and biopsy confirmed LCH. H
Langerhans cell histiocytosis (LCH) has Society. Adoption of a uniform clinical/labopresented problems in diagnosis and in ratory approach to these children, coupled treatment.Thedefinitivediagnosis isapatho-with agreed-upon steps to the pathologic logic one. To advance thorough and uni-identificati